Nirmatrelvir-ritonavir for COVID-19

摘要

1. Ritonavir-boosted nirmatrelvir (marketed as Paxlovid) is a Health Canada-approved oral antiviral medication with activity against SARS-CoV-2: Treatment is indicated for adult (> 18 yr) outpatients with nonhypoxic COVID-19 who are at high risk of severe disease progression (e.g., advanced age, comorbidity, unvaccinated or immunosuppressed). 2. Studies recruited primarily unvaccinated participants, predated the omicron variant and have not yet undergone peer review: According to available data, patients with 5% risk of hospital admission have an estimated number needed to treat to prevent 1 hospital admission of 24 (95% confidence interval 22-29).3'4 The most common adverse effects are dysgeusia, diarrhea, vomiting, increased blood pressure and headache.